SEC Form 4 · accession 0000899866-15-000086
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Hallal
Officer — CEO · Director
Period of report
Mar 31, 2015
Accepted (ET)
Apr 2, 2015 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Mar 31, 2015 | A | 11,270 | $0.00 | A | 144,128 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $173.30 | Mar 31, 2015 | A | 49,275 | A | Mar 31, 2016 | Mar 31, 2025 | Common Stock, par value $.0001 per share | 49,275 | 49,275 | D |
Explanation of responses
- F1Award of restricted stock units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
- F2Stock option award under 2004 Incentive Plan. 25% vests on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.